Physician profile
Bruce Porterfield
NPI 1962451377
$2,475.84
in general payments reported to CMS, 2019-2025
40 companies · $786 in 2025
The $786 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,052 · 2020: $239 · 2021: $128 · 2023: $29.35 · 2024: $242 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,057.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $305.82 | 2019-2020 | |
| Incyte Corporation | $236.88 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $196.35 | 2019-2025 | Opdivo, Opdualag |
| Pfizer INC. | $184.03 | 2019-2025 | |
| Celgene Corporation | $160.97 | 2019-2025 | Reblozyl, Pomalyst |
| Abbvie INC. | $117.57 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $108.58 | 2019-2025 | |
| Astellas Pharma US INC | $107.23 | 2019-2025 | Vyloy, Padcev |
| Array Biopharma INC | $86.65 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Astrazeneca Pharmaceuticals LP | $70.51 | 2019-2025 | Enhertu |
| Merck Sharp & Dohme LLC | $65.27 | 2019-2025 | Keytruda |
| Beone Medicines USA, INC. | $65.12 | 2025 | Brukinsa |
| Beigene USA, INC. | $51.78 | 2024 | Brukinsa |
| Glaxosmithkline, LLC. | $45.34 | 2025 | Ojjaara |
| Amgen INC. | $45.18 | 2019 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $44.61 | 2019-2020 | |
| Verastem, INC. | $39.76 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.86 | 2019 | |
| Genzyme Corporation | $37.33 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.64 | 2019 | |
| Emd Serono, INC. | $31.76 | 2019 | |
| Puma Biotechnology, INC. | $29.94 | 2019 | |
| Mirati Therapeutics, INC. | $29.35 | 2023 | Krazati |
| Daiichi Sankyo INC. | $27.67 | 2025 | Enhertu |
| Coherus Oncology, INC. | $25.78 | 2024 | |
| Seagen INC. | $24.52 | 2019-2020 | |
| Exelixis INC. | $24.48 | 2019 | |
| Secura Bio, INC. | $24.29 | 2019 | |
| Deciphera Pharmaceuticals INC. | $24.09 | 2025 | Romvimza, Qinlock |
| Aveo Pharmaceuticals, INC. | $21.69 | 2025 | |
| Stemline Therapeutics INC. | $21.39 | 2025 | Elzonris |
| Genentech USA, INC. | $20.79 | 2019 | |
| Karyopharm Therapeutics INC. | $20.75 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $20.65 | 2019 | |
| Blueprint Medicines Corporation | $19.40 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $18.02 | 2019 | |
| Kite Pharma, INC. | $17.75 | 2020 | |
| Corcept Therapeutics | $17.12 | 2025 | Korlym |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Porterfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.